The Scottish Referral Guidelines for Suspected Cancer were created to help GPs, the wider primary care team, other clinicians, patients and carers to identify those people who are most likely to have cancer and who therefore require urgent assessment by a specialist. Equally, it is hoped that the guidelines will help clinicians to identify people…
This NICE pathway provides an interactive flowchart of myeloma diagnosis and management using information from both NICE and other sources.
The European Myeloma Network have published recommendations on diagnostic, prognostic and monitoring tests for patients with myeloma.
These guidelines, produced by the National Institute for Health and Care Excellence (NICE), set out new recommendations for the diagnosis, treatment and care of myeloma patients with the aim of providing consistently excellent patient-focused care within the NHS in England. Update information October 2018: Recommendations 1.8.13 to 1.8.17 were replaced by NICE’s guideline on venous thromboembolism in…
The IMWG report on the newly developed revised version of the International Staging System (R-ISS) which incorporates chromosomal abnormalities to develop a more powerful staging system for stratifying myeloma patients.
This paper, produced by an expert panel of the International Myeloma Working Group (IMWG), provides consensus updates on the disease definition of myeloma which now include validated biomarkers in addition to the presence of the traditional ‘CRAB’ criteria.
These updated guidelines, produced by the British Committee for Standards in Haematology (BCSH) and the UK Myeloma Forum, summarise a national consensus of the haematological community involved in the diagnosis and management of myeloma patients. They should be read in conjunction with the BCSH Guidelines on the supportive care of myeloma patients. Bird et al.…
This paper, written by an expert panel on behalf of the International Myeloma Working Group, addresses the need for new uniform response criteria for myeloma patients.
This paper, written by an expert panel on behalf of the International Myeloma Working Group, outlines consensus recommendations for risk stratification for clinical and clinical trial use.